Efficacy of adalimumab as first-line therapy in pediatric Crohn's disease

2017 ◽  
Vol 49 (4) ◽  
pp. e261
Author(s):  
L. Zenzeri ◽  
B. Pigneur ◽  
L. Norsa ◽  
E. Farinelli ◽  
S. Esposito ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?

2013 ◽  
Vol 10 (6) ◽  
pp. 345-351 ◽  
Author(s):  
Laurent Peyrin-Biroulet ◽  
Gionata Fiorino ◽  
Anthony Buisson ◽  
Silvio Danese
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Exclusive enteral nutrition continues to be first line therapy for pediatric Crohn's disease in the era of biologics

2015 ◽  
Vol 83 (1) ◽  
pp. 47-54
Author(s):  
V.M. Navas-López ◽  
J. Blasco-Alonso ◽  
S. Lacasa Maseri ◽  
F. Girón Fernández-Crehuet ◽  
M.J. Serrano Nieto ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Enteral Nutrition ◽  
First Line ◽  
Exclusive Enteral Nutrition ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals CRITICAL ANALYSIS OF ANTI-TNF USE IN THE ERA OF NEW BIOLOGICAL AGENTS IN INFLAMMATORY BOWEL DISEASE

2020 ◽  
Vol 57 (3) ◽  
pp. 323-332 ◽  
Author(s):  
Camila Cunha Gonzaga LIMA ◽  
Natália Sousa Freitas QUEIROZ ◽  
Carlos Walter SOBRADO ◽  
Gustavo Luís Rodela SILVA ◽  
Sérgio Carlos NAHAS
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Long Term Treatment ◽  
Inflammatory Bowel

ABSTRACT BACKGROUND: Inflammatory bowel diseases (IBD), both Crohn’s disease and ulcerative colitis, are chronic immune-mediated diseases that present a relapsing and remitting course and requires long-term treatment. Anti-tumor necrosis factor (anti-TNF) therapy has changed the management of the disease by reducing the need for hospitalizations, surgeries and improving patient´s quality of life. OBJECTIVE: The aim of this review is to discuss the role of anti-TNF agents in IBD, highlighting the situations where its use as first-line therapy would be appropriate. METHODS: Narrative review summarizing the best available evidence on the topic based on searches in databases such as MedLine and PubMed up to April 2020 using the following keywords: “inflammatory bowel disease’’, “anti-TNF agents” and ‘’biologic therapy’’. CONCLUSION: Biological therapy remains the cornerstone in the treatment of IBD. In the absence of head-to-head comparisons, the choice of the biological agent may be challenging and should take into account several variables. Anti-TNF agents should be considered as first line therapy in specific scenarios such as acute severe ulcerative colitis, fistulizing Crohn’s disease and extra-intestinal manifestations of IBD, given the strong body of evidence supporting its efficacy and safety in these situations.

Sign in / Sign up

Export Citation Format

Share Document